Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
Neovascular Age-related Macular Degeneration
![Regeneron Pharmaceuticals](https://trials-media.s3.amazonaws.com/orgs/regeneron-pharmaceuticals.jpeg)
About this trial
This is an interventional treatment trial for Neovascular Age-related Macular Degeneration focused on measuring Eyes, Neovascular, Macular Degeneration, Retina, AMD, VEGF Trap-Eye, Best Corrected Visual Acuity
Eligibility Criteria
Inclusion Criteria:
- Participation in Study VGFT-OD-0605 through week 96.
- In the opinion of the investigator, the study eye has neovascular AMD and may continue to require treatment.
Exclusion Criteria:
- Presence of any condition that would jeopardize the patient's participation in this study.
- Females who are pregnant, breastfeeding, or of childbearing potential, unwilling to practice adequate contraception throughout the study.
Sites / Locations
Arms of the Study
Arm 1
Experimental
Open-label Intravitreal Aflibercept Injection
Open-label Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) 2mg (40 mg/mL) was administered no more frequently than every 4 weeks, but no less frequently than every 12 weeks until amendment 4. Starting with amendment 4, Intravitreal Aflibercept Injection was administered no less frequently than every 8 weeks. Within these limits, the investigator would determine the interval of Intravitreal Aflibercept Injection administration on an as-needed basis according to the protocol-suggested re-treatment criteria, however the injections must have occurred at least every 12 weeks prior to amendment 4, and at least every 8 weeks starting from amendment 4 as noted above.